ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v10i5.835ppharm-187Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCASE REPORTКЛИНИЧЕСКИЙ СЛУЧАЙ ПРИМЕНЕНИЯ КАНАКИНУМАБА У ПАЦИЕНТА С СИСТЕМНЫМ ЮВЕНИЛЬНЫМ ИДИОПАТИЧЕСКИМ АРТРИТОМCLINICAL CASE OF CANAKINUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITISДенисоваР. В.DenisovaR. V.АлексееваЕ. И.AlexeevaE. I.

доктор медицинских наук, профессор, заведующая ревматологическим отделением Научного центраздоровья детей РАМН

PhD, Professor, head of the rheumatology department at the SCCH, dean of the pediatrics faculty at the First Sechenov MSMU

alekatya@ya.ruСлепцоваТ. В.SleptsovaT. V.Научный центр здоровья детей РАМН, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian FederationRussian FederationНаучный центр здоровья детей РАМН, Москва Первый Московский государственный медицинский университет им. И.М. Сеченова, МоскваРоссияScientific Center of Children’s Health, Moscow, Russian Federation First Sechenov Moscow State Medical University, Moscow, Russian FederationRussian Federation201301102013105Педиатрическая фармакология111114Copyright © Денисова Р.В., Алексеева Е.И., Слепцова Т.В., 20132013Денисова Р.В., Алексеева Е.И., Слепцова Т.В.Denisova R.V., Alexeeva E.I., Sleptsova T.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/187

The article presents a case of successful use of therapeutic monoclonal antibodies to interleukin 1 (canakinumab) at severe systemic juvenile idiopathic arthritis. Canakinumab treatment promptly provided reduction in clinical and laboratory disease activity indicators, increase in life quality, development of inactive disease stage and allowed avoiding prescription of glucocorticoids.

системный ювенильный идиопатический артритканакинумабдетиsystemic juvenile idiopathic arthritiscanakinumabchildrenСтатья опубликована при финансовой поддержке ООО «Новартис Фарма» (Россия) в соответствии с внутренними политиками общества и действующим законодательством Российской Федерации.ReferencesCassidy J. T., Petty R. E. Juvenile idiopathic arthritis. In Cassidy J. T., Petty R. E. eds. Textbook of pediatric rheumatology, 6th edn. Philadelphia: WB Saunders. 2011.Cassidy J. T., Petty R. E. Juvenile idiopathic arthritis. In Cassidy J. T., Petty R. E. eds. Textbook of pediatric rheumatology, 6th edn. Philadelphia, WB Saunders, 2011.Prakken B., Albani S., Martini A. Juvenile idiopathic arthritis. Lancet. 2011; 377: 2138–49.Prakken B., Albani S., Martini A. Juvenile idiopathic arthritis. Lancet. 2011; 377: 2138–49.Бзарова Т. М., Алексеева Е. И., Петеркова В. А. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (5): 13–18.Bzarova T. M., Alekseeva E. I., Peterkova V. A. Voprosy sovremennoi pediatrii = Current pediatrics. 2006; 5 (5): 13–18.Kelly A., Ramanan A. V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol. 2007; 19: 477–81.Kelly A., Ramanan A. V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol. 2007; 19: 477–81.Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005; 201: 1479–86.Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 2005; 201: 1479–86.Баранов А. А., Алексеева Е. И., Бзарова Т. М. Протокол ведения пациентов с ювенильным артритом. Вопросы современной педиатрии. 2013; 12 (1): 37–56.Baranov A. A., Alekseeva E. I., Bzarova T. M. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (1): 37–56.Gattorno M., Pelagatti M. A., Meini A., Obici L., Barcellona R., Federici S. et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor–associated periodic syndrome. Arthritis Rheum. 2008; 58: 1516–20.Gattorno M., Pelagatti M. A., Meini A., Obici L., Barcellona R., Federici S. et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor–associated periodic syndrome. Arthritis Rheum. 2008; 58: 1516–20.Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S. et al. The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58: 1505–15.Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S. et al. The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58: 1505–15.Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011; 70: 747–54.Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 2011; 70: 747–54.Nigrovic P. A., Mannion M., Prince F. H., Zeft A., Rabinovich C. E., van Rossum M. A. et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011; 63: 545–55.Nigrovic P. A., Mannion M., Prince F. H., Zeft A., Rabinovich C. E., van Rossum M. A. et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011; 63: 545–55.Nicolino R., Pierre Q., Nico W. et al. A Phase II, Multicenter, Open-Label Study Evaluating Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features. Arthritis & Rheumatism. 2012; 64 (2): 557–567.Nicolino R., Pierre Q., Nico W. et al. A Phase II, Multicenter, Open-Label Study Evaluating Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features. Arthritis & Rheumatism. 2012; 64 (2): 557–567.Nicolino R., Hermine I., Brunner et al. Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. N Engl J Med. 2012; 367: 2396–406.Nicolino R., Hermine I., Brunner et al. Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. N. Engl. J. Med. 2012; 367: 2396–406.Намазова-Баранова Л. С. Научные исследования и инфраструктура платформы «Педиатрия». Педиатрическая фармакология. 2012; 9 (4): 15–24.Namazova-Baranova L. S. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (4): 15–24.

The authors declare that there are no conflicts of interest present.